Clinical Trials Logo

Influenza Type B clinical trials

View clinical trials related to Influenza Type B.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04471038 Active, not recruiting - Influenza Clinical Trials

Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants

Start date: July 29, 2020
Phase: Phase 1
Study type: Interventional

Influenza causes substantial morbidity and mortality worldwide despite available antivirals and vaccines. SAB Biotherapeutics, Inc. has developed SAB-176, an anti-influenza human immunoglobulin (transchromosomic [Tc] bovine-derived) intravenous therapeutic to treat past and current strains of Type A Influenza and Type B Influenza. This study will evaluate the safety, tolerability, and pharmacokinetics of SAB-176 in healthy participants.